Idelalisib for Relapsed Follicular Lymphoma (FL) and Small Lymphocytic Leukemia (SLL) Voluntarily Withdrawn from US Market
This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
There has been concern about drug shortages during the COVID-19 pandemic. The CLL Society investigated these concerns and has been reassured that, at least for ibrutinib, there will be no impacts to the product supply.
Related posts